List view / Grid view
12 December 2009 | By
Automated high content screening platforms are capable of producing thousands of images per day. The challenge is to use appropriate analysis methods to extract the maximum amount of biologically-relevant information from these images. In this article we summarise the basic concepts of image analysis and highlight examples of both open-source…
12 December 2009 | By
Coverage Includes: Compound/siRNA Screening - Pathway Analysis - Data Management - Image Analysis - HCA for Stem Cells - Live-Cell Imaging - Flow Cytometry - Neuronal Screening - New Biological Models for HCA - Novel Probes and Biosensors
12 December 2009 | By
At present, the relevance of Raman Spectroscopy (RS) as an analytical tool in pharmaceutical sciences is increasingly obvious. RS is a mode of vibrational spectroscopy based on inelastic scattering of laser light and, like infrared spectroscopy (IR), provides detailed molecular structure information (see Figure 1A). However, contrary to IR, it…
12 December 2009 | By
Participants: Dr Gordon R Alton, President and CEO, Altonyx Consulting / Dr Scott Bowes Scientist, Novartis / Dr Sheraz Gul, Vice President and Head of Biology, European ScreeningPort / Chris Molloy, Vice President of Corporate Development, IDBS
12 December 2009 | By
In 2010 a diverse group of scientists, engineers and professionals from around the world will come together once again for this laboratory automation event. At LabAutomation2010 participants will develop long-lasting connections through networking and expand their minds by exploring cutting-edge information and strategies.
9 October 2009 | By
A wide and versatile range of analytical techniques are routinely used, indeed are necessary, in pharmaceutical analysis. Over the past decade Raman spectroscopy has increasingly come to the fore as a valuable member of the arsenal of methods used, from both a fundamental and applied perspective, for the interrogation of…
9 October 2009 | By Dr. Nicolas Abatzoglou, Professor and Chairman of the Department of Chemical & Biotechnological Engineering of the Université de Sherbrooke; Pierre-Philippe Lapointe-Garant, PAT Scientist and Jean-Sébastien Simard, Technical Services, both Wyeth Pharmaceuticals
Process analytical technology (PAT) initiatives are now an integral part of developmental efforts in the pharmaceutical industry. Many technical and scientific papers and even dedicated sections appear regularly in several pharmaceutical manufacturing publications. They may be part of a quality by design (QbD) project to better identify and understand critical…
30 July 2009 | By
The understanding of properties of any biological system requires a detailed and quantitative analysis of its parts and their interactions. As different processes within a system occur at defined space and time, each process holds its own optimal observation and investigation technique. One of the most powerful tools to analyse…
30 July 2009 | By Pedro E. Hernandez-Abad, Associate Director; Jun Huang, Principal PAT Scientist II and Saly Romero-Torres, Principal PAT Scientist, both Wyeth Pharmaceuticals
Boards of health like the Food and Drug Administration and European Medicines Agency and ICH guidelines Q8, Q9 and Q10, provide a framework for Quality by Design (QbD) that fully integrates drug substance and drug product development with the principles of Quality Risk Management (QRM), Process Analytical Technology (PAT) and…
29 May 2009 | By
1. How significantly do you feel the Drug Discovery Process has benefited from the application of High Content Analysis techniques? Anthony Davies: Since the mid 1990's High-content analysis (HCA) has primarily been used in the later stages of the pre-clinical drug discovery process. However, as HCA techniques have developed and…
29 May 2009 | By
As the time-to-market of pharmaceutical products has elongated, while its prices are under big pressure, cost saving is currently essential in the pharmaceutical industry.
20 March 2009 | By
Technological advances in robotised microscopy, liquid handling and image processing have enabled the emergence of high content screening where large numbers of specimens are automatically analysed. Here we overview the process discussing potential difficulties and solutions.
There has been a continuous move by the large commercially orientated players involved in Drug Discovery to initiate novel methods to increase income streams and productivity. An example of the former has been the acquisition of companies and their drug pipelines and in the case of the latter, rationalisation of…
7 February 2009 | By
High Content Analysis and Screening technologies (HCA) ushered in a new era in the biomedical research, enabling the scientists to uncover previously unknown disease mechanisms and to introduce innovative approaches to the development of the new generations of therapeutic drugs with a potential to selectively target individual genes, molecules and…
7 February 2009 | By
During the optimisation of drug candidates, improvements in affinity and selectivity play a critical role. This task is usually accomplished by establishing accurate correlations between the affinity/selectivity of different chemical scaffolds and through chemical modifications to a selected scaffold.
